Good reasons for confidential drug prices
Tidsskr Nor Laegeforen. 2019 Mar 11;139(5).
doi: 10.4045/tidsskr.19.0106.
Print 2019 Mar 12.
[Article in
English,
Norwegian]
No abstract available
MeSH terms
-
Confidentiality*
-
Cost-Benefit Analysis
-
Drug Costs*
-
Health Policy
-
Health Priorities
-
Humans
-
Norway